Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Palumbo, Antonio; Chanan‐Khan, Asher; Weisel, Katja; K. Nooka, Ajay; Masszi, Tamás; Beksaç, Meral; Špıčka, Ivan; Hungria, Vânia; Munder, Markus; Mateos, María‐Victoria; M. Mark, Tomer; Qi, Ming; M. Schecter, Jordan; Amin, Himal; Qin, Xiang; Deraedt, William; Ahmadi, Tahamtan; Spencer, Andrew; Sonneveld, Pieter

doi:10.1056/nejmoa1606038

Public

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

Published in New England Journal of Medicine • Aug 24, 2016

Authors:

Antonio Palumbo

Asher Chanan‐Khan

Katja Weisel

Abstract

BACKGROUND: Daratumumab, a human IgGκ monoclonal antibody that targets CD38, induces direct and indirect antimyeloma activity and has shown substantial efficacy as monotherapy in heavily pretreated patients with multiple myeloma, as well as in combination with bortezomib in patients with newly diagn...

Subject

Daratumumab

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!